Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Importance: Neurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to ameliorate AD progression by slowing or stopping the spread and/or accumulation of pathological tau. Objective: To evaluate the safety and efficacy of the monoclonal anti-tau antibody semorinemab in prodromal to mild AD. Design, Setting, and Participants: This phase 2 randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted between October 18, 2017, and July 16, 2020, at 97 sites in North America, Europe, and Australia. Individuals aged 50 to 80 years (inclusive) with prodromal to mild AD, Mini-Mental State Examination scores between 20 and 30 (inclusive), and confirmed β-amyloid pathology (by positron emission tomography or cerebrospinal fluid) were included. Interventions: During the 73-week blinded study period, participants received intravenous infusions of placebo or semorinemab (1500 mg, 4500 mg, or 8100 mg) every 2 weeks for the first 3 infusions and every 4 weeks thereafter. Main Outcomes and Measures: The primary outcomes were change from baseline on the Clinical Dementia Rating-Sum of Boxes score from baseline to week 73 and assessments of the safety and tolerability for semorinemab compared with placebo. Results: In the modified intent-to-treat cohort (n = 422; mean [SD] age, 69.6 [7.0] years; 235 women [55.7%]), similar increases were seen on the Clinical Dementia Rating-Sum of Boxes score in the placebo (n = 126; Δ = 2.19 [95% CI, 1.74-2.63]) and semorinemab (1500 mg: n = 86; Δ = 2.36 [95% CI, 1.83-2.89]; 4500 mg: n = 126; Δ = 2.36 [95% CI, 1.92-2.79]; 8100 mg: n = 84; Δ = 2.41 [95% CI, 1.88-2.94]) arms. In the safety-evaluable cohort (n = 441), similar proportions of participants experienced adverse events in the placebo (130 [93.1%]) and semorinemab (1500 mg: 89 [88.8%]; 4500 mg: 132 [94.7%]; 8100 mg: 90 [92.2%]) arms. Conclusions and Relevance: In participants with prodromal to mild AD in this randomized clinical trial, semorinemab did not slow clinical AD progression compared with placebo throughout the 73-week study period but did demonstrate an acceptable and well-tolerated safety profile. Additional studies of anti-tau antibodies may be needed to determine the clinical utility of this therapeutic approach. Trial Registration: ClinicalTrials.gov Identifier: NCT03289143.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“5 or 1, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)16 Delayed Memory Index scores of 85 or less, and evidence of significant cerebral amyloid pathology confirmed by either β-amyloid (Aβ) PET scan (n = 341; [18F]florbetaben, [18F]florbetapir, [18F]flutemetamol, or [18F]NAV4694 via central…”
MethodSelf-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519 · cited 1×
“5 or 1, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)16 Delayed Memory Index scores of 85 or less, and evidence of significant cerebral amyloid pathology confirmed by either β-amyloid (Aβ) PET scan (n = 341; [18F]florbetaben, [18F]florbetapir, [18F]flutemetamol, or [18F]NAV4694 via central…”
MethodStaging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“5 or 1, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)16 Delayed Memory Index scores of 85 or less, and evidence of significant cerebral amyloid pathology confirmed by either β-amyloid (Aβ) PET scan (n = 341; [18F]florbetaben, [18F]florbetapir, [18F]flutemetamol, or [18F]NAV4694 via central…”
MethodPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · cited 1×
“5 or 1, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)16 Delayed Memory Index scores of 85 or less, and evidence of significant cerebral amyloid pathology confirmed by either β-amyloid (Aβ) PET scan (n = 341; [18F]florbetaben, [18F]florbetapir, [18F]flutemetamol, or [18F]NAV4694 via central…”
MethodTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease
Wesseling, H., Mair, W., Kumar, M., Schlaffner, C. N., Tang, S., Beerepoot, P., Fatou, B., Guise, A. J., Cheng, L., Takeda, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.029 · Cited by 688
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
Self-citationLongitudinal tau PET in ageing and Alzheimer’s disease
Jack, C. R., Wiste, H. J., Schwarz, C. G., Lowe, V. J., Senjem, M. L., Vemuri, P., Weigand, S. D., Therneau, T. M., Knopman, D. S., Gunter, J. L., et al. (2018) · Brain · doi:10.1093/brain/awy059 · Cited by 452 · cited 1×
“5 or 1, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)16 Delayed Memory Index scores of 85 or less, and evidence of significant cerebral amyloid pathology confirmed by either β-amyloid (Aβ) PET scan (n = 341; [18F]florbetaben, [18F]florbetapir, [18F]flutemetamol, or [18F]NAV4694 via central…”
MethodTau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
Dujardin, S., Commins, C., Lathuiliere, A., Beerepoot, P., Fernandes, A. R., Kamath, T. V., De Los Santos, M. B., Klickstein, N., Corjuc, D. L., Corjuc, B. T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0938-9 · Cited by 438 · cited 1×
“5 or 1, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)16 Delayed Memory Index scores of 85 or less, and evidence of significant cerebral amyloid pathology confirmed by either β-amyloid (Aβ) PET scan (n = 341; [18F]florbetaben, [18F]florbetapir, [18F]flutemetamol, or [18F]NAV4694 via central…”
MethodPontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357
Self-citationTau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
Chang, C.-W., Shao, E., & Mucke, L. (2021) · Science · doi:10.1126/science.abb8255 · Cited by 263
Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review
Gibbons, G. S., Lee, V. M. Y., & Trojanowski, J. Q. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2505 · Cited by 257 · cited 1×
“5 or 1, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)16 Delayed Memory Index scores of 85 or less, and evidence of significant cerebral amyloid pathology confirmed by either β-amyloid (Aβ) PET scan (n = 341; [18F]florbetaben, [18F]florbetapir, [18F]flutemetamol, or [18F]NAV4694 via central…”
MethodPontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P. M., Southekal, S., Arora, A. K., et al. (2019) · Brain · doi:10.1093/brain/awz090 · Cited by 249
From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Colin, M., Dujardin, S., Schraen-Maschke, S., Meno-Tetang, G., Duyckaerts, C., Courade, J.-P., & Buée, L. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02087-9 · Cited by 187
Cited by
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
Emerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197
Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S.-Y., Du, M.-Q., & Liu, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1206572 · Cited by 165
Ebell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
Metadata
- Authors
- Teng, E., Manser, P. T., Pickthorn, K., Brunstein, F., Blendstrup, M., Sanabria Bohorquez, S., Wildsmith, K. R., Toth, B., Dolton, M., Ramakrishnan, V., Bobbala, A., Sikkes, S. A. M., Ward, M., Fuji, R. N., Kerchner, G. A., Tauriel Investigators, Farnbach, P., Kyndt, C., O'Brien, T., Yassi, N., Schwartz, R., Lieten, S., Vandenberghe, R., Vanhee, F., Bergeron, R., Black, S., Cohen, S., Frank, A., Nisker, W., Tartaglia, M. C., Justesen, A., Alexandersen, P., Nielsen, S., Areovimata, A., Anthony, P., Belliard, S., Blanc, F., Ceccaldi, M., Dubois, B., Krolak-Salmon, P., Mollion, H., Pasquier, F., Grimmer, T., Kottke-Arbeiter, M. E., Laske, C., Peters, O., Polivka, D., von Arnim, C., Bruno, G., De Lena, C., Cassetta, E., Centonze, D., Logroscino, G., Dautzenberg, P., Rutgers, S., Prins, N., Czarnecki, M., Dobryniewski, J., Ilkowski, J., Klodowska, G., Krygowska-Wajs, A., Kucharski, R., Mickielewicz, A., Ratajczak, M., Zboch, M., Zielinski, T., Abizanda Soler, P., Agüera Morales, E., Baquero Toledo, M., Blesa González, R., Boada Rovira, M., Del Olmo Rodriguez, A., Krupinski, J., Linazasoro Cristobal, G., López Arrieta, J., Riverol Fernandez, M., Sanchez Del Valle Diaz, R., Viñuela Fernandez, F., Jonsson, M., Östlund, H., MacSweeney, J. E., Mummery, C., Agronin, M., Ala, T., Bond, W., Schaerf, F., Brody, M., Edwards, K., Forchetti, C., Sood, A., Geldmacher, D., Goldstein, M., Goodman, I., Hart, D., Honig, L., Justiz, W., Levey, A., Losk, S., Marshall, G., Martinez, W., McAllister, P., McElveen, W. A., Maldonado-Robles, O., Murphy, C., Nair, M., Nair, A., Omidvar, O., Oskooilar, N., Porsteinsson, A., Rosenbloom, M., Russell, D., Sajjadi, S. A., Pierce, A., Salloway, S., Sha, S., Shah, R., Sharma, S., Smith, W., Stein, L., Stoukides, J., Thein, S., Turner, R., Watson, D., & Weisman, D.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2022-08-01
- Volume
- 79
- Issue
- 8
- Pages
- 758
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W4282547758
- Cited by
- 202
- References
- 20
- FWCI
- 20.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.